Truvestments Capital LLC Sells 2,010 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Truvestments Capital LLC significantly reduced its holdings in Charles River Laboratories International by 78.5%, dropping from 2,562 shares to 552 shares in the first quarter, with a current value of approximately $83,000.
• Several large investors have also altered their positions in the company, with Northwestern Mutual increasing its stake by an impressive 1,366.7%, while other firms adjusted their holdings to strengthen investment in the stock.
• Charles River Laboratories reported better-than-expected earnings with a EPS of $3.12 for the last quarter, surpassing analyst estimates, and its revenue increased to $1.03 billion, reflecting a 0.6% year-over-year growth.

Truvestments Capital LLC reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 78.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 552 shares of the medical research company's stock after selling 2,010 shares during the period. Truvestments Capital LLC's holdings in Charles River Laboratories International were worth $83,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of CRL. Wahed Invest LLC increased its holdings in shares of Charles River Laboratories International by 6.5% in the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after buying an additional 81 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after buying an additional 86 shares during the period. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after buying an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after buying an additional 105 shares during the period. Finally, Veracity Capital LLC raised its position in Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock valued at $496,000 after buying an additional 107 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of CRL traded down $2.58 on Tuesday, reaching $160.73. 250,196 shares of the stock traded hands, compared to its average volume of 1,242,444. The stock's 50-day moving average price is $159.63 and its 200-day moving average price is $148.82. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of -120.83, a P/E/G ratio of 5.22 and a beta of 1.47. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the previous year, the company earned $2.80 earnings per share. The business's revenue was up .6% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CRL shares. Barclays boosted their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a research report on Thursday, August 7th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Five investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $175.69.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).